Radiation-induced pemphigus vulgaris of the breast.

Pemphigus vulgaris is a rare autoimmune mucocutaneous bullous disease. Patients with a history of pemphigus vulgaris - who need radiotherapy - may show a long lasting bullous cutaneous manifestation, typical of pemphigus, within radiation fields. The literature describes fewer than 20 radio-induced cases. While systematic corticosteroid therapy has proven to be useful, topical treatment used in association with corticosteroid therapy is rarely described. To our knowledge the use of modern dressing products has never been described. We report our experience in a case in which modern dressing products were usefully associated to systemic therapy.

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study.

BACKGROUND: Intensification of chemoradiation for advanced head and neck squamous cell carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy or with chemotherapy showed favourable toxic profile with positive results in both combinations. Therefore, cetuximab could intensify chemoradiation without worsening toxicity. We conducted a phase II study of chemoradiation and cetuximab. PATIENTS AND METHODS: Eligible patients had stage III-IV M0 HNSCC. Treatment consisted of three cycles of cisplatin (20 mg/m(2)/day × 5 days) and fluorouracil (200 mg/m(2)/day × 5 days) rapidly alternated to three split courses of radiotherapy up to 70 Gy and concurrent weekly cetuximab. The primary end point of the study was complete response (CR) rate. Secondary end points were toxicity, progression-free survival (PFS) and overall survival (OS). RESULTS: Fourty-five patients were enrolled: median age was 56 years, 38 had stage IV disease and 40 nodal involvement. CR occurred in 32 patients (71%). PFS and OS was 21+ months and 32.6+, respectively. Acute grade 3-4 toxic effects were in the expected range, but grade 3 radiodermatitis occurred in 33 patients. CONCLUSIONS: The combination of cetuximab, cisplatin, fluorouracil and radiotherapy leads to a very high proportion of CR and it is feasible with toxic effects similar to those expected by radiochemotherapy. The only unexpected toxicity was skin toxicity: grade 3 radiodermatitis occurred in 73% of the patients.

[Radical radiotherapy in T2N0 glottic laryngeal carcinomas]. / La radioterapia radicale nei carcinomi laringei glottici T2N0.

The present work analyzes the clinical results obtained at the Istituto del Radio in Brescia, Italy, using radiotherapy in the treatment of T2N0 glottic carcinomas. The analysis covers a sampling of 127 patients who had been treated using fixed field with 60Co or linear accelerator (high energy photons) technique delivering a minimum target dose of 60 Gy over the course of a 6-week period; 200 cGy a day. The purpose of the present study was to evaluate: treatment response 3 months after treatment was suspended using the WHO nomenclature; Overall Survival Rate and Actuarial Disease-Free Survival Rate at five and ten years from the end of treatment comparing the results obtained in cases of T2a and T2b; biological cost of treatment in terms of late recurrences. Three months after treatment had ended, a complete response was seen in 95% of the patients. The overall survival was 85% at five years while the NED survival was 67% at five years. Surgical salvage made it possible to treat 44% of those who did not respond to radiotherapy or who had a recurrence. Late recurrence rate was 4.7%. The clinical results are slightly lower than those obtained in the literature for surgical series in terms of survival probability. They were, however, certainly better in terms of good vocal preservation.